Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Meet virtually with our team and complete your medical intake from home ideal for clients across the greater Los Angeles area
However, despite previous reports on the potential advantage posed by GLP1-based multi-agonists in the management of obesity and metabolic disease, as recently exemplified by the dramatic body weight-lowering actions of the GLP1/GIP dual agonist, tirzepatide 47 , to our knowledge, no study has addressed to date the pharmacological characterization of GLP1-based unimolecular multi-agonists for management of reproductive and metabolic alterations of PCOS, using suitable preclinical models, as pre-requisite for their application in clinics
PubMed This content is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment
doi: 10.1126/scitranslmed.aat3392 55 HeimbrgerSMBergmannNCAugustinRGasbjergLSChristensenMBKnopFK
US$ 20.50
US$ 26.98
US$ 27.83
US$ 22.52
US$ 28.67
